Please wait while the formulary information is being retrieved.
RYDAPT (MIDOSTAURIN)
- Acute myeloid leukemia with FLt3 mutation
- Aggressive systemic mastocytosis
- Mast cell leukemia
- SM with associated hematological neoplasm
25 mg capsule
- 4 capsules (100 mg) by oral route 2 times per day approximately 12 hours apart
Acute myeloid leukemia with FLt3 mutation
- 2 capsules (50 mg) by oral route 2 times per day approximately 12 hours apart on days 8-21 of each treatment cycle
Aggressive systemic mastocytosis
- 2 capsules (50 mg) by oral route 2 times per day approximately 12 hours apart
- 4 capsules (100 mg) by oral route 2 times per day approximately 12 hours apart
Mast cell leukemia
- 2 capsules (50 mg) by oral route 2 times per day approximately 12 hours apart
- 4 capsules (100 mg) by oral route 2 times per day approximately 12 hours apart
SM with associated hematological neoplasm
- 2 capsules (50 mg) by oral route 2 times per day approximately 12 hours apart
- 4 capsules (100 mg) by oral route 2 times per day approximately 12 hours apart
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- amiodarone
- amiodarone in dextrose,iso-osm
- artemether-lumefantrine
- clozapine
- Clozaril
- Coartem
- Cordarone
- deferiprone
- disopyramide
- dronedarone
- droperidol
- Fazaclo
- Ferriprox
- Geodon
- Multaq
- Nexterone
- Norpace
- Norpace Cr
- Orap
- Pacerone
- pimozide
- thioridazine
- Versacloz
- ziprasidone HCl
- ziprasidone mesylate
Severe
Moderate
- Ablavar
- alfuzosin
- Anzemet
- Apokyn
- apomorphine
- arsenic trioxide
- Avelox
- Avelox Abc Pack
- Avelox In Nacl (iso-osmotic)
- bedaquiline
- Betapace
- Betapace Af
- Caprelsa
- Celexa
- Cipro
- Cipro In D5W
- Cipro Xr
- ciprofloxacin
- ciprofloxacin (mixture)
- ciprofloxacin in D5W
- citalopram
- Complera
- crizotinib
- dasatinib
- Diskets
- dofetilide
- dolasetron
- Dolophine
- Edurant
- emtricitab-rilpivirine-tenofov
- eribulin
- escitalopram oxalate
- ezogabine
- Fareston
- fingolimod
- gadofosveset trisodium
- Gilenya
- Halaven
- Haldol
- Haldol Decanoate
- haloperidol
- haloperidol decanoate
- haloperidol lactate
- Invega
- Invega Sustenna
- Invirase
- Istodax
- Kaletra
- lapatinib
- Levaquin
- Levaquin In 5 % Dextrose
- levofloxacin
- levofloxacin in D5W
- Lexapro
- lopinavir-ritonavir
- methadone
- Methadone Intensol
- Methadose
- moxifloxacin
- moxifloxacin in NaCl (iso-osm)
- Nexavar
- nilotinib
- norfloxacin
- Noroxin
- Noxafil
- ondansetron
- ondansetron HCl
- ondansetron HCl (PF)
- paliperidone
- paliperidone palmitate
- pasireotide
- pazopanib
- posaconazole
- Potiga
- propafenone
- Qualaquin
- quetiapine
- quinine sulfate
- rilpivirine
- romidepsin
- Rythmol
- saquinavir mesylate
- Seroquel
- Seroquel Xr
- Signifor
- Sirturo
- sorafenib
- Sorine
- sotalol
- Sotalol Af
- Sprycel
- Tasigna
- telavancin
- tetrabenazine
- Tikosyn
- toremifene
- Trisenox
- Tykerb
- Uroxatral
- vandetanib
- vemurafenib
- Vibativ
- Votrient
- Xalkori
- Xenazine
- Zelboraf
- Zofran
- Zofran Odt
- Zuplenz
- Lactating mother
Contraindicated
- Interstitial lung disease
- Pregnancy
Severe
Moderate
- None
RYDAPT (MIDOSTAURIN)
- Acute myeloid leukemia with FLt3 mutation
- Aggressive systemic mastocytosis
- Mast cell leukemia
- SM with associated hematological neoplasm
- Anemia
- Infection
- Neutropenic disorder
- Thrombocytopenic disorder
- Acute abdominal pain
- Constipation
- Diarrhea
- Dyspnea
- Edema
- Elevated serum lipase
- Epistaxis
- Fatigue
- Fever
- Headache disorder
- Hyperglycemia
- Lymphopenia
- Musculoskeletal pain
- Nausea
- Petechiae
- Stomatitis
- Upper respiratory infection
- Vomiting
More Frequent
Severe
Less Severe
- Acute myocardial infarction
- Bacterial sepsis
- Gastritis
- Gastrointestinal hemorrhage
- Hypersensitivity drug reaction
- Hypertension
- Hypotension
- Interstitial lung disease
- Interstitial pneumonitis
- Kidney disease with reduction in GFR
- Opportunistic fungal infection
- Pericardial effusion
- Pleural effusions
- Prolonged QT interval
- Pulmonary edema
- Thrombotic disorder
- Arthralgias
- Cellulitis
- Chemotherapy-induced hyperuricemia
- Chills
- Disturbance of attention
- Dry skin
- Dyspepsia
- Eyelid edema
- Heart failure
- Hematoma
- Hemorrhoids
- Hypercalcemia
- Hyperhidrosis
- Insomnia
- Pain in oropharynx
- Tremor
- Vertigo
- Weight gain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Pulmonary congestion
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Midostaurin
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Midostaurin
- Severity Level:
D
- Additional Notes: Based on drug pharmacology and animal data developmental toxicity is possible.
Contraindicated
Midostaurin
Mfr doesn't rec breastfeeding during tx & for 4 months after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfr doesn't rec breastfeeding during tx & for 4 months after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Acute myeloid leukemia with FLt3 mutation | |
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| Aggressive systemic mastocytosis | |
| C96.21 | Aggressive systemic mastocytosis |
| Mast cell leukemia | |
| C94.3 | Mast cell leukemia |
| C94.30 | Mast cell leukemia not having achieved remission |
| SM with associated hematological neoplasm | |
| C96.21 | Aggressive systemic mastocytosis |
| D47.02 | Systemic mastocytosis |
| 0-9 | A-Z |
|---|---|
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C94.3 | Mast cell leukemia |
| C94.30 | Mast cell leukemia not having achieved remission |
| C96.21 | Aggressive systemic mastocytosis |
| C96.21 | Aggressive systemic mastocytosis |
| D47.02 | Systemic mastocytosis |
Formulary Reference Tool